Gualberto Ruano, Richard Judson | GenomeWeb

Gualberto Ruano, Richard Judson


Genaissance Pharmaceuticals CSO Gualberto Ruano will resign from the company on Aug. 31. Ruano, who was ousted from the chief executive’s slot one year ago, will also leave Genaissance’s board of directors. Richard Judson will replace him as CSO.

Judson, 44, joined Genaissance in 1999. Since August 2000 he has served as senior vice president of medical affairs and informatics, and had been responsible for leading the development of the company’s HAP Technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.